Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TMPRSS2:ERG



This biomarker is also known as:
  • T2S:ERG,

View in BioMuta


TMPRSS2:ERG gene fusions are a common genetic event in prostate cancer. These fusions are specific for prostate cancer and have also been observed in precursor lesions. Since TMPRSS2:ERG fusions are not seen in every prostate cancer, their utility is in assays combined with other biomarkers, such as PCA3.


QA State: Curated
Type: Gene
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


TMPRSS2:ERG urine assay for prostate cancer detection is in studies in CLIA lab and is undergoing phase 3 validation.

Performance Comment

The combined measurement of PCA3 and TMPRSS2:ERG in urine outperformed serum PSA for prostate cancer diagnosis. The detection of TMPRSS2:ERG fusion in urine has greater than 90% specificity and 94% positive predictive value for prostate cancer detection. Increased TMPRSS2:ERG transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.